Vera Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vera Therapeutics, Inc. - overview
Established
2016
Location
South San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2016 by Marshall Fordyce, Vera Therapeutics, Inc. , f. k. a Trucode Gene Repair, Inc.
operates as a biotechnology company that develops novel therapeutics to develop new therapies. In January 2021, Vera Therapeutics, Inc. raised USD 80 million in a Series C funding led by Abingworth, with participation from Alexandria Venture Investments, Fidelity Investments, Longitude Capital, Octagon Capital Investments, Surveyor Capital, GV, Kleiner Perkins, and Sofinnova Ventures. The company has raised a total of USD 114 million in funding.
In 2021, Vera Therapeutics was acquired by NeuBase Therapeutics Inc. In May 2021, Vera Therapeutics, Inc. raised USD 47. 85 million in an IPO, selling 4.
35 million shares at USD 11 per share. The company is trading on the Nasdaq Global Market under the ticker symbol VERA. Vera Therapeutics provides clinical research and development for the treatment of immunological and inflammatory diseases to enable patients in the treatment of IgA nephropathy (IgAN), which is a rare autoimmune disease. In addition, the company also develops and commercializes atacicept in all indications from Merck KGaA, Darmstadt, Germany, a leading science, and technology company.
The company generates revenue by offering the developed therapies to pharmaceutical companies. The company plans to use its proceeds from January 2021 funding to support the advancement of its lead clinical candidate, atacicept, a novel inhibitor of B cells and plasma cells, in patients with IgA nephropathy (IgAN). In addition, the company also plans to scale its manufacturing capabilities and expand the therapeutic pipeline in immunologic and inflammatory diseases.
Current Investors
Kleiner Perkins, GV, Sofinnova Investments
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.veratx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Vera Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Spektrum | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.